Abstract
In recent years, the development of ustekinumab and vedolizumab has further improved the treatment of inflammatory bowel disease (IBD), offering additional therapeutic options to achieve induction and maintenance of remission in both ulcerative colitis (UC) and Crohn's disease (CD). However, data about the impact on extra-intestinal manifestations (EIMs) of IBD are limited [1]. In this issue, Margolin et al. [2] have reported the effect of ustekinumab and vedolizumab in EIMs of IBD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
